中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2014年
11期
2554-2555
,共2页
梁卫明%陈义雄%陈建业%戴维%黄杰
樑衛明%陳義雄%陳建業%戴維%黃傑
량위명%진의웅%진건업%대유%황걸
原发性肝癌%可溶性B7-H4%手术治疗%介入治疗
原髮性肝癌%可溶性B7-H4%手術治療%介入治療
원발성간암%가용성B7-H4%수술치료%개입치료
Primary liver carcinoma%Soluble B7-H4%Operation%Interventional therapy
目的 观察原发性肝癌(PLC)患者血清中可溶性B7-H4水平以及介入治疗和手术治疗对其表达的影响.方法 酶联免疫吸附试验(ELISA)法检测32例正常人以及62例PLC患者血清可溶性B7-H4水平,并比较18例Ⅰ期PLC患者手术前后以及25例Ⅱ期PLC患者介入治疗前后血清可溶性B7-H4水平.结果 PLC患者血清可溶性B7-H4水平[(46.83±9.98) μg/L]明显高于正常对照组[(30.24±6.43) μg/L,P＜0.叭],血清可溶性B7-H4水平与PLC患者性别、年龄无明显相关,与临床分期明显相关;Ⅲ期[(53.67±10.57) μg/L]明显高于Ⅱ期[(47.32±7.99) μg/L]、Ⅱ期明显高于Ⅰ期[(40.04±8.50) μg/L]、Ⅰ期明显高于正常对照组,两两比较差异有统计学意义(P＜0.05);手术后PLC患者血清可溶性B7-H4水平[(35.49±8.54) μg/L]明显低于手术前[(40.04±8.50) μg/L]、介入治疗后PLC患者血清可溶性B7-H4水平[(45.02±7.84) μL]明显低予介入治疗前[(47.32±7.99) μg/L],两者差异有统计学意义(P＜0.01).结论 检测血清可溶性B7-H4有助于监测PLC治疗效果.
目的 觀察原髮性肝癌(PLC)患者血清中可溶性B7-H4水平以及介入治療和手術治療對其錶達的影響.方法 酶聯免疫吸附試驗(ELISA)法檢測32例正常人以及62例PLC患者血清可溶性B7-H4水平,併比較18例Ⅰ期PLC患者手術前後以及25例Ⅱ期PLC患者介入治療前後血清可溶性B7-H4水平.結果 PLC患者血清可溶性B7-H4水平[(46.83±9.98) μg/L]明顯高于正常對照組[(30.24±6.43) μg/L,P＜0.叭],血清可溶性B7-H4水平與PLC患者性彆、年齡無明顯相關,與臨床分期明顯相關;Ⅲ期[(53.67±10.57) μg/L]明顯高于Ⅱ期[(47.32±7.99) μg/L]、Ⅱ期明顯高于Ⅰ期[(40.04±8.50) μg/L]、Ⅰ期明顯高于正常對照組,兩兩比較差異有統計學意義(P＜0.05);手術後PLC患者血清可溶性B7-H4水平[(35.49±8.54) μg/L]明顯低于手術前[(40.04±8.50) μg/L]、介入治療後PLC患者血清可溶性B7-H4水平[(45.02±7.84) μL]明顯低予介入治療前[(47.32±7.99) μg/L],兩者差異有統計學意義(P＜0.01).結論 檢測血清可溶性B7-H4有助于鑑測PLC治療效果.
목적 관찰원발성간암(PLC)환자혈청중가용성B7-H4수평이급개입치료화수술치료대기표체적영향.방법 매련면역흡부시험(ELISA)법검측32례정상인이급62례PLC환자혈청가용성B7-H4수평,병비교18례Ⅰ기PLC환자수술전후이급25례Ⅱ기PLC환자개입치료전후혈청가용성B7-H4수평.결과 PLC환자혈청가용성B7-H4수평[(46.83±9.98) μg/L]명현고우정상대조조[(30.24±6.43) μg/L,P＜0.팔],혈청가용성B7-H4수평여PLC환자성별、년령무명현상관,여림상분기명현상관;Ⅲ기[(53.67±10.57) μg/L]명현고우Ⅱ기[(47.32±7.99) μg/L]、Ⅱ기명현고우Ⅰ기[(40.04±8.50) μg/L]、Ⅰ기명현고우정상대조조,량량비교차이유통계학의의(P＜0.05);수술후PLC환자혈청가용성B7-H4수평[(35.49±8.54) μg/L]명현저우수술전[(40.04±8.50) μg/L]、개입치료후PLC환자혈청가용성B7-H4수평[(45.02±7.84) μL]명현저여개입치료전[(47.32±7.99) μg/L],량자차이유통계학의의(P＜0.01).결론 검측혈청가용성B7-H4유조우감측PLC치료효과.
Objective To detect the serum soluble B7-H4 (sB7-H4) level of patients with primary liver carcinoma (PLC),and to investigate the effects of interventional therapy and operation on it.Methods Enzyme linked immunosorbent assay (ELISA) were available to detect the level of serum sB7-H4 in 62 cases of patients with PLC and 32 cases of normal control subject,compared with 18 cases stage Ⅰ of patients with PLC pre-and post-operation,25 cases stage Ⅱ of patients with PLC pre-and postinterventional therapy.Results The level of serum sB7-H4 were elevated in all subgroups of patients with PLC [(46.83 ±9.98) μg/L] compared to the controls [(30.24 ±6.43) μg/L,P ＜0.01],serum sB7-H4 was not correlated sex and age,and with clinical stage; the serum sB7-H4 level in stage Ⅲ [(53.67 ± 10.57) μg/L] was higher in comparison with stage Ⅱ [(47.32 ±7.99) μg/L],in stage Ⅱ it was higher than that in stage Ⅰ [(40.04 ±8.50) μg/L],and in stage Ⅰ it was higher than that in normal control subject (P ＜ 0.05),the serum sB7-H4 levels were remarkably reduced in patients with PLC after operation or interventional therapy (P ＜0.01).Conclusion The serum sB7-H4 could be taken as an effective indicator monitoring the treatment effect for PLC.
